
Dianthus Therapeutics Investor Relations Material
Latest events

M&A Announcement
Dianthus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dianthus Therapeutics Inc
Access all reports
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
DNTH
Country
🇺🇸 United States